Across TCGA pan-cancer cohorts, PSG5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PSG5 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PSG5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSG5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUSC, UCEC, and CHOL are the cancer types where PSG5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.273	0.615	.025	6	view →
UCEC	DFS	Median	All	1.000	0.630	.035	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	DFS	Median	III,IV	0.707	0.455	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PSG5 tumor-vs-normal RNA expression · all PSG5 data types